1. Home
  2. CUE vs JVSA Comparison

CUE vs JVSA Comparison

Compare CUE & JVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • JVSA
  • Stock Information
  • Founded
  • CUE 2014
  • JVSA 2021
  • Country
  • CUE United States
  • JVSA Hong Kong
  • Employees
  • CUE N/A
  • JVSA N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • JVSA
  • Sector
  • CUE Health Care
  • JVSA
  • Exchange
  • CUE Nasdaq
  • JVSA NYSE
  • Market Cap
  • CUE 48.0M
  • JVSA 83.2M
  • IPO Year
  • CUE 2018
  • JVSA 2024
  • Fundamental
  • Price
  • CUE $0.68
  • JVSA N/A
  • Analyst Decision
  • CUE Strong Buy
  • JVSA
  • Analyst Count
  • CUE 3
  • JVSA 0
  • Target Price
  • CUE $3.00
  • JVSA N/A
  • AVG Volume (30 Days)
  • CUE 313.6K
  • JVSA 96.6K
  • Earning Date
  • CUE 08-13-2025
  • JVSA 01-01-0001
  • Dividend Yield
  • CUE N/A
  • JVSA N/A
  • EPS Growth
  • CUE N/A
  • JVSA 719.53
  • EPS
  • CUE N/A
  • JVSA 0.27
  • Revenue
  • CUE $7,991,000.00
  • JVSA N/A
  • Revenue This Year
  • CUE N/A
  • JVSA N/A
  • Revenue Next Year
  • CUE $23.84
  • JVSA N/A
  • P/E Ratio
  • CUE N/A
  • JVSA $13.40
  • Revenue Growth
  • CUE 13.83
  • JVSA N/A
  • 52 Week Low
  • CUE $0.45
  • JVSA $3.12
  • 52 Week High
  • CUE $1.99
  • JVSA $19.28
  • Technical
  • Relative Strength Index (RSI)
  • CUE 47.91
  • JVSA N/A
  • Support Level
  • CUE $0.65
  • JVSA N/A
  • Resistance Level
  • CUE $0.71
  • JVSA N/A
  • Average True Range (ATR)
  • CUE 0.08
  • JVSA 0.00
  • MACD
  • CUE 0.00
  • JVSA 0.00
  • Stochastic Oscillator
  • CUE 38.62
  • JVSA 0.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About JVSA JVSPAC ACQUISITION CORP

JVSPAC Acquisition Corp is blank check company.

Share on Social Networks: